Continuum DAP-R 3-Year DOI (Canada)

This page contains information on Continuum DAP-R 3-Year DOI for veterinary use.
The information provided typically includes the following:
  • Continuum DAP-R 3-Year DOI Indications
  • Warnings and cautions for Continuum DAP-R 3-Year DOI
  • Direction and dosage information for Continuum DAP-R 3-Year DOI

Continuum Dap-r 3-year Doi

This treatment applies to the following species:
Manufacturer: Merck Animal Health

Canine Distemper-adenovirus Type 2-parvovirus-rabies Vaccine

Modified Live Virus and Killed Virus

Product Description: Continuum™ Dap-r Is A Modified Live Virus Vaccine Containing Attenuated Strains Of Canine Distemper Virus (cdv), Adenovirus Type-2 (cav-2), Parvovirus (cpv), And Inactivated Rabies Virus. continuum™ Dap-r Is Presented In A Desiccated Form With Rabies Diluent Provided For Reconstitution. The Attenuated Distemper Virus Strain Used In continuum™ Dap-r Is The Onderstepoort Strain. The Parvovirus Component Is Patented* cpv Strain 154®, Which Is An Attenuated Parvovirus Strain Of Canine Origin. continuum™ Dap-r Is Produced With High-titered Cpv And Cdv Components That Are Immunogenic. The Manhattan Strain Of Adenovirus Type-2 In continuum™ Dap-r Confers Protection Against Canine Infectious Hepatitis Caused By Cav-1 Without The Adverse Reactions Associated With Cav-1, Such As Corneal Edema (“blue Eye”). The Pasteur Strain Of Rabies Virus Is Used In continuum™ Dap-r.

indications

For the vaccination of healthy dogs as an aid in the prevention of disease caused by rabies, canine distemper virus, canine adenovirus type-1, and canine parvovirus for up to 3 years following initial and booster vaccinations. Protection against CAV-2 was demonstrated by robust serological responses in dogs at 36 months following vaccination.

Safety Data

Extensive safety testing has demonstrated that CPV STRAIN 154® and the distemper component of CONTINUUM™ DAP-R are safe when given to puppies as young as 4 weeks of age. CONTINUUM™ DAP-R was demonstrated to be >95% reaction-free when administered to dogs of various age, breed, and sex.

Efficacy Data

Efficacy and non-interference of the modified live viral and killed rabies fractions have been established.

For rabies efficacy, sixty-three seronegative pups were randomly assigned to two groups: Group 1 contained 32 pups and Group 2 contained 31 non-vaccinated control pups. Pups in Group 1 were vaccinated at 8 weeks of age with CONTINUUM™ DAP and at 12 weeks of age with CONTINUUM™ DAP-R. All dogs were held in strict isolation for 3 years (36 months) following the last vaccination and then challenged with virulent rabies virus. Serum antibody titers for CAV-2, CDV, CPV, and rabies were measured throughout the isolation period (Table 1). The geometric mean antibody titers (GMTs) remained at high levels throughout the isolation period.

Table 1. Geometric mean titers (GMTs) in dogs following vaccination.

Virus Fraction (Assay)

Pre-
vac

Months After Booster Vaccination*

1

3

6

9

12

18

24

30

36

CAV-2 (SN)

<2

357

614

1562

1470

1448

632

672

1149

595

CDV (SN)

<2

454

1191

153

168

227

89

55

140

184

CPV (HI)

<10

564

530

1027

387

482

311

223

142

216

Rabies (RFFIT)

<5

116

34

111

28

46

18

17

35

15

* Dogs were vaccinated initially at 8 weeks of age with CDV, CAV-2, and CPV followed by a booster vaccination with CDV, CAV-2, CPV, and rabies at 12 weeks of age.

At 36 months post vaccination, the GMT for CAV-2 was 1:595, for CDV was 1:184, and for CPV was 1:216, and for rabies was 1:15. Thirty-six months following vaccination, all dogs were challenged with virulent rabies virus (New York City Street Virus, masseter muscle challenge).

Rabies Challenge

Following challenge with virulent rabies, 30 of the 31 controls and 4 of the 32 vaccinates developed signs typical of rabies including excessive salivation, urination, anorexia, dysphagia, depression, paralysis, coma, and death. Rabies infection status was confirmed using fluorescent antibody (FA) testing of brain tissue. Clinical signs of rabies were prevented in 88% of vaccinated dogs; whereas, 97% of control dogs were infected, exceeding the USDA requirements of 80% for rabies vaccine efficacy studies.

Table 2. Rabies Challenge.

treatment

Dogs

# Surviving Challenge

Fluorescent Antibody Positive

CONTINUUM™ DAP-R

32

28 (88%)

4

Control

31

1 (3%)

30

The prevented fraction is the proportion of infection prevented by the vaccine relative to the infection rate in nonvaccinated dogs.

Table 3. Prevented Fraction.

fraction

Continuum™ Dap-r

Prevented Fraction

95% Confidence Interval

Rabies

88%

58%, 96%

The study results demonstrate that the modified-live viruses in CONTINUUM™ DAP provide protection in 7 weeks-of-age or older dogs for a minimum of 3 years following second vaccination.

The study results demonstrate that the killed rabies fraction in CONTINUUM™ DAP-R provides protection against virulent rabies challenge in 12 weeks-of-age or older dogs for a minimum of 3 years following vaccination.

Directions For Use

Aseptically reconstitute the desiccated vaccine with the rabies vaccine diluent provided and administer 1 mL by the subcutaneous route. Initial vaccination of healthy dogs may be given as early as 12 weeks of age, with a booster injection for rabies using CONTINUUM™ DAP-R or monovalent rabies vaccine administered 1 year later. Revaccinate every 3 years with a single dose of CONTINUUM™ DAP-R.

Precautions

1. Recommended storage temperature 2-7°C (35-45°F). Do not freeze.

2. Shake well before use.

3. Use contents promptly once reconstituted.

4. Non-chemically sterilized needles and syringes should be used for administration of vaccine.

5. Avoid vaccinating pregnant bitches.

6. Administration of epinephrine may be indicated in the event of an anaphylactic reaction.

7. Contains gentamicin, neomycin, polymyxin B, and thimerosal as preservatives.

8. Burn this vial and all unused contents.

9. Only healthy animals should be vaccinated. Animals incubating any disease or animals stressed due to shipping, malnutrition, or parasitism may not achieve or maintain an adequate immune response.

10. The rabies diluent contains a pH indicator as an added feature. If the rabies diluent changes in color, do not use.

11. This product is not hazardous when used according to directions supplied. A material safety data sheet (MSDS) is available upon request. This and any other consumer information can be obtained by calling toll free Intervet Canada Corp. Customer Service at 1-866-683-7838.

Supplied

Cartons of 25 1-dose/1-mL desiccated vaccine vials and 25 1-mL rabies diluent vials. Packaged in recyclable plastic containers.

Sales Product Code No.

006774

For Veterinary Use Only

U.s. Veterinary License No. 165a

Intervet Inc., Millsboro, De 19966

For technical enquiries, call toll free 1 888 306-0069.

™Trademark of Intervet International B.V., used under license by Intervet Canada Corp.

*U.S. Patent Nos. 4,810,494, 5,316,764

AL 411

Rev. 900645501

Nac No.

12081913
MERCK ANIMAL HEALTH
Intervet Canada Corp.

16750 ROUTE TRANSCANADIENNE, KIRKLAND, QC, H9H 4M7
Order Desk:   514-428-7013
Toll-Free:   866-683-7838
Fax:   Toll-free 888-498-4444; local 514-428-7014
Website:   www.merck-animal-health.ca
Every effort has been made to ensure the accuracy of the Continuum DAP-R 3-Year DOI information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.

Copyright © 2014 North American Compendiums. Updated: 2014-04-11

(web5)